Protagonist Therapeutics, which is developing peptide-based oral drugs for gastrointestinal disease, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The company counts Eli Lilly and John & Johnson among its investors.
The Milpitas, CA-based company was founded in 2001 and plans to list on the Nasdaq under the symbol PTGX. Leerink Partners, Barclays and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
